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Abstract 
Biotechnology is still in the early stage of development. It offers a window of opportunity for 
emerging developing countries catching up. Scientific research and industrial applications of bio-
technology in China have been rapidly developing. The paper examines whether Chinese biotech-
nology is catching up leaders in the field. The approach follows the conceptual framework of 
Malerba’s Sectoral System of Innovation and Production (Malerba and Nelson, 2012), comple-
mented by Mathew’s (2002) insight into strategies for latecomer firms. The data for the empirical 
analysis are mostly from China’s Science and Technology and High Technology Industry Year-
books and bibliographic data on Chinese scientific publications and patenting.  Brief case studies of 
outstanding organizations complement the statistical analysis.  The results of the study show that 
China is fast catching up in scientific research, and more moderately in industrial production of 
biotechnology-based manufacturing of drugs and medical devices. 
----------------------------- 
This research note was carried out in collaboration with Groupe de recherche en économie et 
développement international (GREDI) from the University of Sherbrooke and was published as a 
working paper 2014-07. 
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1. Introduction 
The emergence of biotechnology opened a window of opportunity for a few large 
emerging developing countries to catching up with the leaders in the field. This paper 
focuses on the case of China’s catching up in scientific research and principal 
biotechnology applications in manufacturing of pharmaceuticals and medical equipment 
and devices.   
Modern biotechnology is a science-based technology. Its development, use and 
applications are closely associated with the high level of scientific education and public 
research. Most dedicated biotechnology firms are small and at the beginning of their 
existence; R&D activities are often more important than production of goods and services. 
They require highly specialized personnel and their industrial development is dependent on 
appropriate public policies and regulation. Government funding and venture capital are 
important sources of financing during the long process to commercial success. 
China’s planners believe that the modern biotechnology will help resolve the pressing 
need for affordable human health services by introducing new, cost-effective 
pharmaceuticals and diagnostic methods and medical devices. They earmarked 
biotechnology for accelerated scientific and technological development in the Bio-industry 
‘Eleven-Five’ development Program in 2007. The announcement in April 2009 of the long 
awaited China’s health care reform with a budget of 850 billion Yuan promising affordable 
universal health care by 2020, will give Chinese biotechnology further impetus. The Health 
Reform that started in 2011 has increased the demand for and investment in health care 
including in pharmaceutical and medical device research and production. It has created 
huge solvent demand and opportunity for development of pharmaceuticals and medical 
devices.
1
  
                                                 
1
 The funding is part of China’s stimulus package: http://www.chinabusinessreview.com/chinas-healthcare-
reform-how-far-has-it-come/ 
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The objective of the paper is to assess whether China has been catching up in 
biotechnology research and industrial production of human health-related applications 
during the last ten to fifteen years, the early growth period, well covered by the Science and 
Technology statistics for up to about 2010.
2
  
The structure of the paper is as follows. The next section presents the theoretical 
framework, references to the literature and the methodology for an empirical approach and 
the data.  
Section 3 focuses on reforms after 1978. The first part presents the reforms of principal 
institutions framing the Chinese biotechnology system.  The second part deals with their 
impact on the evolution of resources and performance of the Chinese biotechnology 
scientific research as measured by the rapid growth of scientific articles related to 
biotechnology. 
Section 4 focuses on the industrial applications of biotechnology in manufacturing of 
pharmaceuticals and medical equipment & devices. It underlines the structural and 
performance differences between the incumbent chemical manufacturing of medicines and 
the ascending biological and biochemical medicine both in production and in R&D as 
revealed by Chinese statistics of high technology industries. It also examines the striking 
differences between the domestic private, state-owned and the foreign-invested enterprises. 
The evolution of patenting by domestic biotechnology enterprises in China and the U.S. 
and short case studies of several leading enterprises complete the text. 
The last section discusses the principal findings and concludes with a brief section on 
challenges facing China’s biotechnology catching up. 
                                                 
2
 Coincidentally, the China’s National Bureau of Statistics introduced a significant change in statistical data 
classification which breaks the High Technology data series in 2011 and makes them difficult or impossible 
to compare with previous years. Thus, except for some more recent data from other sources, the effects of the 
Health reform-related investment could not be included in this paper.    
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2. Theoretical framework and empirical approach 
The literature on catching up originated with Genschenkron (1962). The latecomer 
firms (LCFs) have to be able to absorb more advanced technologies (Abramovitz, 1986).  
The catch up process is typically sectorial. The Sectorial System of Innovation and 
Production (SSIP) (Malerba and Orsenigo, 1997; Breschi et al., 2000) provides a theoretical 
framework for the analysis.  The resource-poor LCF has to adopt a strategy for learning the 
dynamic capabilities needed to compete in the technology-intensive markets and catchup 
with the forerunners (Mathews, 2002, Lee and Lim, 2001). Two collections of studies on 
catching up by developing countries appeared recently: Malerba and Mani (2009) and 
Malerba and Nelson (2012).  
As its name and nature suggest, biotechnology is not a sector, or even an industry. It is 
more akin to Perez and Soete’s (1988) technology system (or in SSIP jargon, technological 
regime). The present main industrial application of biotechnology is manufacturing of 
medicines by biological and biochemical processes and, to a lesser extent, other health 
care-related products and services.  
2.1 The technological regime 
The technological regime of biotechnology is a combination of four components (the 
knowledge base, technological opportunity, appropriability of innovations and 
cumulativeness of technical advances that describe the chief traits of the technological 
environment in which take place innovation and industrial  applications of biotechnology 
(Breschi et al., 2000).  
The knowledge base 
Applications of modern biotechnology in manufacturing of drugs, medical 
equipment and devices and related services are closely related to the progress of the 
scientific research. The sciences underlying biotechnology and life sciences are progressing 
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rapidly, and their results are highly uncertain.  Owing to its multidisciplinary character and 
public impact, the product cycle of biotech drugs is long and expensive.   
Technological opportunity 
Since biotechnology is still in the early stage of its development, especially in 
China, it provides technological opportunities which may provide a “window” allowing 
developing countries to catch up (Perez and Soete, 1988; Niosi and Reid, 2007).  
Appropriation regime  
Empirical studies are unanimous in indicating that patents and trademarks are the 
most useful and frequently used statutory instruments to protect against imitation and 
provide a means to appropriate innovation-related benefits in chemical, pharmaceutical and 
special equipment industries. A strong patent signals to prospective partners, lenders, 
investors and funding agencies the technological prowess of the patentee and may serve as 
collateral for financing (Levin et al. 1987; Baldwin and Hanel, 2003; Hanel, 2006).  
Cumulativeness of technical advances  
The original innovators, Genentech, Amgen and few others are still leaders of 
manufacturing of biologic drugs – the biotechnological knowledge is still very cumulative. 
The capacity of a new technology to generate new technological opportunities declines over 
time; c.f. the decreasing returns to the chemical-based “small molecule” drug research, 
illustrated by the falling number of new chemical drugs, the declining productivity and 
increasing cost of R&D. 
2.2 The principle actors and institutions 
The three main actors of the biotechnology system are public research organizations 
(PRO), universities, and industrial enterprises. The evolution of the pharmaceutical SSIP 
and its biotechnology using component are evolving in an institutional environment 
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determined by government institutions and policies. Some of them are sector specific like 
the Chinese State Food and Drug Administration (SFDA).  Others are national, like the 
financial system or the intellectual property regime, within the rules governing international 
economy, such as the WTO’s TRIPS agreements which determine the mandatory 
international standards of intellectual protection.  
Catch up strategies by latecomer firms  
In contrast to  “start-ups or spin-offs” in a developed country, latecomer firms 
(LCF)  often do not have the advantage of access to knowledge and technology resources of 
the parent firm, university or public research organization (PRO), existing market, linkages 
and supporting institutions. The successful LCFs overcome their competitive disadvantages 
through repetitive application of linkage, resource leverage, and learning in an international 
environment dominated by leading incumbent foreign firms. These CU strategies are 
suggested in the context of globalization with inter-firm networks and abundant financial 
resources on the one side and technological solutions on the other (Mathews, 2002; Lee and 
Lim, 2001). 
2.3 Empirical approach and data 
The paper is data-driven, based mainly on Chinese official statistics. The principal 
sources are High Technology Industry (HT) and Science and Technology (ST) Statistical 
Yearbooks (Ybk). These statistics are exceptional in many ways. The data reflect the 
government’s priority to catch up with the technologically advanced western countries. 
This may put in question their reliability. The statistics also have problems that make them 
for some purposes incoherent and their use often frustrating. Despite these potential and 
real shortcomings, the statistics provide a wealth of information on the development of 
biotechnology in China.  
The nomenclature of H-T industries includes the pharmaceutical sector, constituted by 
three branches defined by their technologies: ‘Manufacture of chemical medicine,’ 
‘Manufacture of traditional Chinese medicine’ and ‘Manufacture of biological and 
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biochemical chemical products,’ i.e. biotechnology-based production of 
“biopharmaceutical” medicines. The other health care-related industry also using 
biotechnology is ‘Manufacturing of medical equipment and appliances.’ Original 
bibliometric analysis of scientific publications and patenting in China and in the US PTO 
and references to trade literature and our interviews of biotechnology organizations in 
Guangdong province complete the study. 
3
 
3. Institutional Reforms and Their Impact on Research in 
Health-related Biotechnology  
A series of reforms reoriented the Chinese economy from the rigid planning to an 
increasingly market-oriented private enterprise sector framed by policies of reformed and 
new institutions progressively integrated into globalized international environment. The 
first part of this section presents an overview of reforms of institutions framing the Chinese 
biotechnology system (science and technology policy, state support of science and 
technology, the financial system, State Food and Drug Administration (SFDA) and 
intellectual property protection system). The second part deals with the impact of reforms 
on the evolution of resources and performance of the Chinese biotechnology-related 
scientific research in PROs and universities.   
3.1 Reforms  
 Before 1978, Public Research Organizations (PRO) were practically the only 
institutions conducting scientific research. The best were affiliated with the Chinese 
Academy of Sciences. Their role was to conduct mission–oriented projects and provide 
R&D services to industry. Universities trained the scientific manpower and industry 
executed projects conceived by PROs. There was a gap between what the PRO did and 
what firms needed. Industry relied mainly on imitated and imported technology (OECD, 
2009, Liu and White, 2001).  
                                                 
3 Highlights of the survey are presented in more detail in Hanel et al., (2013). 
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A series of market-oriented reforms drastically reduced the funding of PROs, 
introduced competition and encouraged research institutes, as well as universities, to set up 
spin-off companies and run enterprises.   Later reforms abolished most industry specific 
ministries and transformed their research institutes into technology-based enterprises and 
technology service agencies. Closures of institutes and reductions of R&D personnel 
followed until the adoption of the China’s Medium & Long Term Scientific and 
Technological Development Plan (MLP) Guidelines in 2006.   The share of scientific 
research performed by PROs has been falling while increasing in universities. Enterprise 
sector started rapidly to conduct R&D activities.  
The budget cuts and staff reductions created a leaner, more efficient PRO system as 
indicated by the increasing share of Scientist and Engineers in total employment of PROs 
from 52.9% in 1998 to 69.2% in 2008.   Despite the reduced percentage of government 
appropriation for S&T, owing to Chinese fast economic growth the funding of PROs 
increased in constant prices six-times from 1987 to 2008.    
The inflation-adjusted Chinese total R&D intramural expenditures increased from 1995 
to 2010 annually by an average rate of 21.6%. The R&D expenditures as the proportion of 
GDP increased from 0.57% in 1995 to 1.76% in 2010 and it is approaching 2% in 2014. 
The R&D personnel surpassed 2.5 million persons in 2010.    
Due to the pruning of PROs and rising R&D activity in the private sector, the 
proportion of China’s R&D personnel  employed in basic research has been declining 
steadily from close to 10% in the late 90s to 6.8% in 2011.  Moreover, contrary to their 
original mandate to concentrate on basic research, PROs still spend more than half of their 
R&D budget on development and only 11% on basic research. In comparison, Universities 
allocated to basic research about 40% of their R&D budget in 2010.  Industrial enterprises 
are almost exclusively pursuing development; their scientific research activities are 
minimal. The Chinese scientific research system is not yet sufficiently oriented toward 
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basic research needed to support the innovation-based economy, the publicized goal of 
Chinese planners. 
Government Support of Scientific and Industrial Research in Biotechnology 
Development of biotechnology and modern research-based pharmaceutical industry 
were among the top priorities of the “Eleven five” year plan (2006-2010) and the national 
'Medium to Long Range Program Outline for Scientific and Technological Development 
(2006-2020).' The Government ‘plans,’ among other things, China to have three Nobel 
laureates by 2020. The ‘162-Drug development program’ and the $12 billion New Mega 
Drug Development Program allocates impressive funding for the development of 
innovative drugs and large scale bio-enterprises (Scott (2012); ChinaAccess4EU, 2012). It 
is not clear whether these initiatives include projects included in ongoing programs such as 
the National High Technology R&D Program 863 (allocating to biotechnology about 20-
25% in the past), the Basic Research program, Program 973 and others (OECD, 2007).  
The three levels of Government are the principal source of funding of scientific 
research in PROs (85%) and universities (59%) in 2009. Direct government support for 
R&D executed in enterprises is, however, relatively modest. Government funded 8% of 
intramural R&D expenditures of manufacturing of Biological medicine, 5% of Chemical 
medicine and only 4% of medical equipment and appliances industry.    
In addition to direct grants, a vast program of various fiscal and other incentives 
supports R&D and innovation activities, especially in medium and large enterprises. 
Against economic logic, the Governments subsidize small firms less than the large ones. 
The three levels of government endeavor to create biotechnology innovative clusters 
by creating ‘Bioindustry bases’ and building all over the country high-and new 
technological development zones for biopharmaceutical research organizations and industry 
(Prevezer (2008; Zhang et al.,2010; Hanel et al., this volume).    
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Financial System 
The Chinese financial system is highly regulated and opaque. The badly needed 
reforms are slow, and ineffectual. Banks’s priority is to fund large state-owned enterprises. 
Banks are reluctant to finance the privately-run small and medium size high-tech 
companies.  Investment in real estate and infrastructure is more profitable than uncertain 
long-term private high-tech projects.   
Both local (mainly government-funded) and international VC investments are 
increasing in China. But since biopharmaceutical projects need a longer commitment and 
are riskier than non-innovative projects, VC invests mainly in the export-intensive 
consumer electronics and computers.   
A recent study of Life sciences venture capital investments in Brazil, China, India 
and South Africa found that VC activity in biotechnology-related projects was muted; only 
10.4% of their dollar weighted portfolio was invested in sciences, and a mere 0.3% in 
innovative biotechnology (Chakma et al., 2013).  
VC investment in life sciences (both innovative and non-innovative) has been 
fluctuating widely since the global financial crisis. First, it fell to $318million in 2009, then 
it more than tripled to over one billion the following year before falling again by more than 
40% in 2011.  
After investing in promising projects and developing them, VC has to find a 
profitable “exit” to recoup their investment. The most popular exit strategy is selling the 
new VC supported company on the stock market. An increasing number of larger, 
successful biopharmaceutical firms, clinical research organizations and medical equipment 
manufacturers had successful IPOs in Shanghai, Shenzhen, Hong Kong and New York. The 
stock market is, however, not a solution for the small start-ups and medium size firms at the 
stage when they have difficult access to funding.  
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The total value of initial public offerings (IPOs) of drug companies (including an 
unknown share of the VC invested ones) has fluctuated even more than the VC, albeit with 
an increasing trend, as did mergers and acquisitions, many of them with foreign companies. 
Cross-border partnering deals were also on the rise (Figure 1). 
Figure 1. Investment activity in Chinese life sciences, VC, IPO and M&A. (Millions of US 
dollars) 
 
Source: China Bio, China Life Sciences 2010: A giant Leap Forward (2011). 
and China Bio, China Life Sciences 2012: From Local to Global (2012). 
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China Food and Drug Administration 
Created 1998, reorganized and renamed several times, the CFDA is responsible for 
the approval and regulation of drugs, cosmetics and food. The Administration introduced in 
2003 good laboratory practice (GLP) standards and stipulated that clinical research 
organizations (CROs) could conduct clinical trials for their clients in China (Zhou, 2007). 
Since 2004, all pharmaceutical manufacturers have to obtain CFDA certificate of good 
manufacturing practices.  
The approval process is similar to procedures of the U.S. FDA, with which CFDA 
has close ties. The U.S. FDA’s 13-person staff in China has trained more than 1,600 
manufacturers and regulators on United States safety standards (U.S.FDA, 2014). The 
principal CFDA’s handicap is the lack of competent human resources resulting in a 
complicated and slow regulatory system. It takes Chinese CROs 10 to 18 months to obtain 
approval for clinical tests. In India it takes only four months, in Singapore two and the U.S. 
a single one (Christie, 2012). 
Patent System  
Effective protection of intellectual property is of upmost importance for the 
development of new drugs. Before the mid-nineties, like in many industrialized countries 
earlier, patenting of chemical and pharmaceutical inventions in China and other developing 
countries was limited to production technologies. Product inventions such as new 
medicines were not patentable.  The IP regime was designed to encourage import 
substitution as a means to develop the national pharmaceutical industry.  
The creation of the World Trade Organization fundamentally changed the rules of 
international trade.  The WTO adopted the Agreement on Trade-related Aspects of 
Intellectual Property Rights known as TRIPs that imposed minimal standards of IP 
protection to all countries. Product patents became mandatory in all fields, including food, 
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chemicals, pharmaceuticals and biotechnology products. Patent protection was universally 
extended to 20 years. 
China joined WIPO in 1980, signed Paris Convention and adopted its first-patent 
law in 1984. It adopted a TRIPs patent regime in 1995 and achieved full compliance in 
2000. The next amendment in 2009 improved IP protection in China and at the same time 
addressed some Chinese concerns (Li, 2010; Hanel et al., 2011).  
According to Pricewaterhouse Coopers (2009) protection of intellectual property in 
China's pharmaceutical industry has improved significantly. According to their survey, half 
of the multinational pharmaceutical companies were “quite optimistic” and some “very 
optimistic” regarding the intellectual protection in China.  The positive impact of IP 
reforms on patenting by Chinese biotechnology inventors is presented in Section 4.3.  
3.2 Evolution of Scientific Resources and Capabilities in  
Biotechnology  
The essential factor of the research system is the qualified scientific and engineering 
personnel trained by the higher education system in China and abroad.  
Education in Chinese universities  
The number of students newly enrolled in biochemistry and drugs programs 
undergraduate and junior colleges reached 76 758 in 2011, the total enrollment was 237 
580 and 85 344 students graduated.  While the numbers are there, the quality of training in 
Chinese universities is less impressive. In response to specific questions in our survey 
regarding human resources for the biotechnology R&D, it was often mentioned that it is 
difficult to find and hire competent personnel capable of doing innovative research. The 
Chinese education system is blamed for not adequately training students for research. There 
is lot of imitation and sometimes falsification of research results by researchers impatient 
for glory and riches.  In contrast to the foreign practice, the Chinese system does not 
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tolerate failure in research. The long gestation of biotechnology research projects, their high 
cost and uncertain results encourage promising graduates to study abroad or accept 
employment in foreign firms. Several respondents recognized the importance of training 
their employees.   
Evolution of personnel engaged in biotechnology scientific research  
The evolution of pharmaceutical research personnel in (1) Public Research 
Organizations, (2) universities and (3) in the industry is presented in Table 1. The number 
of research personnel increased faster in industry than in PROs and universities. R&D in 
enterprise is, in fact, almost exclusive development (see details in the Industry section 
below).   
The top public research institution is the Chinese Academy of Sciences (CAS) with 
most research institutes concentrated in Beijing. After an initial decline, R&D employment 
increased from 2007 to 2010 by about 15% annually, adding more than one thousand R&D 
positions in the three years.  By 2010, the scientific personnel engaged in medical and 
pharmaceutical research at PROs and universities is about equal (Table 1.).  
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Table 1. R&D Personnel Conducting Pharmaceutical Research in Public Research Organiza-
tions, Higher Education and Industry 
 
  
( full time equivalent person years) 
   Public Research Org.    Higher Education Industry Total 
  Medical &  Pharmacy Manufacturing   
  pharmaceutical     of medicines   
Year products       
1999 (2000) 2 336 1 523 16 750 20 609 
          
2005 n.a. 2 174 26 910 n.a. 
          
2007 2 047 2 422 34 380 38 849 
          
2008 2 441 2 728 55208 60 377 
          
2009 2 886 2,625 70 065 72 954 
          
2010 3 086 3093 81766  * 87 945 
     Sources: China Science and Technology Yearbook, 2010 and earlier years and High-Tech. Industry 
Yearbook 2011 and earlier years. 
Notes: The allocation of R&D to broadly defined pharmaceuticals is only approximate.  
The designations are those used in Science and technology Yearbook for each of the three organi-
zations, PRO, HE and HT industry.  
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Returnees  
A fundamental component of the Chinese biotechnology knowledge base is the 
large and growing number of highly qualified and experienced scientists, engineers, 
managers and other professionals returning to their homeland after studies, university 
research, teaching and professional business career abroad (Figure 2.). 
Figure 2. Annual Number of Returnees 
 
Sources: China Bio LLC, (2012) China Life Science 2012: From Local to Global, and 
http://biotechine.blogspot.ca/2013/08/pharma-r-in-china-role-of-returnees.html 
Their contribution to the nascent biotechnology industry has been widely 
recognized (Prevezer, 2008, 2006; Baeder and Zielenziger, 2010 pp.3, 17). Like in the 
corporate sector, returnees also constitute the majority of senior positions in China’s top 
scientific and academic institutions.   Studies of biology and health related sciences are 
popular among the Chinese students, and they are returning to they are homeland in 
increasing numbers.   
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  According to our survey, biotechnology enterprises founded by returnees are more 
likely to conduct R&D then the other ones. They tend to collaborate more with their foreign 
scientific and business contacts than with the local ones for two reasons:  (1) the technical 
level of the former is more advanced, and they can access tacit information, and (2) they are 
not well integrated with the local business networks, where they have more to gain from 
building contacts with the local party and government officials because these are key to 
success in China (Rowen et al. 2008).  
Some entrepreneurs maintain a hybrid company; one part in the U.S., Canada or EU 
and another one in China and circulate between the two. 
3.3 Is Biotechnological Research in China Catching up with the 
Scientific Frontier?  
Given China’s position as a latecomer, the first objective of its scientific research is 
absorbing, assimilating, replicating and applying the current state of biotechnology used by 
the leaders of the field.  Biotechnology scientific research is often a “use-inspired” basic 
research as illustrated by the conceptual model of the Pasteur’s Quadrant, contributing to 
both basic understanding and applied innovation.  (Stokes, 1997; Hermhans et al. 2008). 
Results of basic and applied Chinese biotechnology research are diffused by scientific 
publications in Chinese and increasingly in English.  
Publications of Chinese Scientific Research in Biotechnology  
The number of scientific articles in biotechnology authored by Chinese scientists 
and engineers in PROs and Chinese Universities has increased exponentially from 1996 to 
2008. Almost two-thirds of BT publications were related to health-related issues (22 423). 
The remaining third of articles deals with BT in agriculture and food (3 374) and in other 
biotechnology subjects (7 336). The residual (2378) deals with unidentified, biotechnology 
related subjects. Altogether, Chinese researchers published 35 110 publications from 1996 
to 2008 (Figure 3.). However, Chinese articles are not yet widely cited and their impact, 
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even though improving, is limited. China’s share of world’s scientific publications in 
biology has increased from 1.1% in 1997 to 9.9% in 2011 (Figure 4). 
Figure 3. Evolution of the Number of Scientific Publications in Biotechnology, by Authors 
from PR of China, 1996-2008 
 
Source: Tabulation of Scopus data by SCIENMETRIX  
Note: * The count for Year 2008 is incomplete- that explains the change of the trend in 2007.   
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Figure 4. Chinese Share of World’s Total Number of Scientific Publications in Biotechnology 
 
Source, U.S. National Science Foundation, Science and Engineering Indicators 2014,  
Appendix, Table 5-50 
 
Researchers from the twelve best universities authored two-thirds of the total 
number of articles in health-related biotechnology published worldwide from 1996 to 2007 
by the top 15 Chinese institutions, compared to one-third published by authors affiliated 
with PROs i.e. the Chinese Academy of Science and Academies of Agricultural and 
Medical Sciences as shown in Table 2.  Universities appear to be contributing more than 
PROs to advancement of biopharmaceutical knowledge and training of qualified personnel.   
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Table 2. Number of articles in health-related biotechnology 
     
% of total  
 
Organisation 
1996-
99 
2000--
2003 
2004-
2007 
1996-
2007 biotechnology 
1 Chinese Academy of Sciences 309 613 1171 2093 52,0 
2 Fudan University 53 303 559 915 65,9 
3 Chinese Academy of Medical Sciences 164 207 374 745 65,3 
4 Zhejiang University 31 145 542 718 78,2 
5 Peking University 41 203 393 637 70,9 
6 Sichuan University 4 103 435 542 70,8 
7 
Huazhong University of Science and Tech-
nology 19 85 431 535 62,6 
8 Peking Union Medical College 97 132 281 510 84,3 
9 Sun Yat-sen University 7 47 358 412 60,1 
1
0 Tsinghua University 44 108 258 410 68,7 
1
1 Shanghai Jiao Tong University 1 37 356 394 73,5 
1
2 Wuhan University 22 97 264 383 65,6 
1
3 
East China University of Science and Tech-
nology 47 61 199 307 60,7 
1
4 China Agricultural University 15 34 170 219 45,0 
1
5 Chinese Academy of Agricultural Sciences 18 23 125 166 35,5 
 
Total 872 2198 5916 8986 
average %  
64.9 
Source: Tabulation of Scopus data by SCIENMETRIX  
 
Chinese scientists are increasingly publishing with co-authors from abroad.  The 
number of internationally co-authored articles has been growing fast, but slower (19%/year) 
than the growth of articles by Chinese authors  (25%/year), see Table 3. Hence, the rapid 
growth of the total number of Chinese biotechnology publications cannot be attributed to 
collaboration with foreign co-authors as suggested by Yu (2007).  
Chinese scientists are increasingly publishing with co-authors from abroad.  The 
number of internationally co-authored articles has been growing fast, but slower (19%/year) 
than the growth of articles by Chinese authors (25%/year), see Table 3. Hence, the rapid 
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growth of the total number of Chinese biotechnology publications cannot be attributed to 
collaboration with foreign co-authors as suggested by Yu (2007).  
Table 3. Number of health-related biotechnology publications with international collaboration 
 
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
       
2008* 
With collaboration 95 104 120 140 125 114 147 290 346 467 568 646 638 
All articles 368 379 568 710 767 919 1 072 1 502 1 797 2 599 3 368 4 124 3 849 
Collaboration % 26% 27% 21% 20% 16% 12% 14% 19% 19% 18% 17% 16% 17% 
              
Source :  Computed by Science-Metrix; data 
Scopus (Elsevier)         
* Data for 2008 incomplete. 
           
 
The comparison of the explosive growth of BT publications with the slower growth 
of R&D personnel active in biotechnology scientific research suggests a significant 
increase of research productivity.   Part of it may be attributed to capital deepening. The 
other part of the explanation is improved organization, incentives and increased domestic 
competitive pressure, especially in universities.  
In the ranking of articles published in Nature Journals, China is the top Asia-Pacific 
nation in five Nature journals in 2012.   Its strongest showing was in Nature Genetics. The 
Beijing Genomic Institute- Shenzhen was the top-ranking Chinese institution from the 
Asian-Pacific region publishing in Nature biotechnology in 2012.  
Is China Catching up Human Health-related Applications of Biotechnology ? 
CIRST – Note de recherche | page 21 
BGI-Shenzhen sequencing “factory”in Hong Kong 
The joint venture between BGI-Shenzhen and the Chinese Hong Kong University 
(CHKU) created the largest gene sequencing capacity in the world. BGI-Shenzhen is 
partnering with research laboratories all over the world. It has created a network of 
affiliates in the U.S., BGI Americas and BGI Europe, in Denmark, to be close to potential 
partners and customers. In March 2013, BGI acquired the U.S. Complete Genomics, a 
leader in human genomic sequencing which became a separately run wholly owned 
subsidiary of BGI-Shenzhen.   
The short and impressive history of BGI-Shenzhen is a typical example of the 
Chinese strategy of overcoming of competitive disadvantage – or in this case, creating a 
competitive advantage- through linkage, resources leverage, and learning as argued by 
Mathews (2002).  
There can be no doubt that the productivity of the Chinese biology and biotechnology–
related scientific research has been improving. Chinese scientists are rapidly catching up 
with the world biotechnology leaders. 
4. Industrial applications of biotechnology   
According to a mandatory survey of biotechnology firms, manufacturing of 
biomedicines and human health applications in China accounted for between two-thirds and 
three-quarters of sales revenues of modern biotechnology in 2003 (OECD, 2006). This 
paper centers on human health-related applications of biotechnology in manufacturing of 
medicines and medical equipment & appliances.   
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The Pharmaceutical Sector and its Biopharmaceutical Component  
The Chinese Pharmaceutical sector (or manufacturing of medicines) has three 
components using distinct knowledge bases and technology regimes:  
 (1) Manufacturing of medicines by chemical processes, 
 (2) Manufacturing of Chinese traditional medicine, and 
 (3) Manufacturing of biopharmaceuticals and other health care related products by 
biological and biochemical processes.  
Each of the components has its own, distinct, but interrelated knowledge base 
reflecting successive stages of understanding of human life, starting with the traditional 
Chinese herbal medicine, followed by manufacturing of chemical medicines and the most 
recent one based on modern biotechnology. They are essential parts of the health care 
system, evolving within the common institutional environment, subject to similar 
constraints, market forces and policies.  
The question is whether the nascent Chinese manufacturing of bio-pharmaceutical 
medicines has laid foundations for a sustained catch up process. More specifically, is there 
evidence (1) that the Chinese biotechnology industry is more dynamic than local 
manufacturing of chemical medicines – how do they compare?  (2) Is it catching up with 
the forerunners?      
Manufacturing of medical equipment and devices  
Some medical equipment and devices use biotechnology in addition to other 
technologies (electronics, information and communication, electro-optic and fine 
mechanics, etc.). Both manufacturing of biopharmaceuticals and medical equipment & 
devices are new components of the life sciences complex. 
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4.1 Manufacturing of Medicines by Biotechnology-based Processes  
The majority of Chinese biotechnology firms are manufacturing bio-similar products 
based on imitation, production under license or under contract for foreign firms. Some also 
collaborate with foreign MNC in drug discovery R&D (Zhou, 2007). They are in intensive 
competition among themselves and with the brand name products of leading MNC firms 
that dominate some segments of the Chinese pharmaceutical market. Foreign brand 
medicines command higher prices, often in spite of not being protected by patents. 
Bioplan and Associates (2008) classified the 60 top ranking manufacturers of 
biotechnology–based medicines into two groups:  
 (i) Recombinant DNA (rDNA) and Monoclonal antibodies (MAbs) products 
 (ii) Manufacturers of Vaccines and Blood Products.  
Recombinant DNA (rDNA) and Monoclonal Antibodies (MAbs) Products 
About half of the companies in this group specialize in  rDNA products; one-quarter 
is combining manufacturing of rDNAs with production of chemical medicines. Only three 
companies are producing (MAbs) products. The rest are producing various combinations of 
the above. The dedicated biotechnology firms are mostly medium or small size. The low 
concentration of the industry and the modest average size of the firm typical of entry stage 
of a new technology regime suggest ample technological opportunities.  
The history of the leading biopharmaceutical company 3SBio Inc. is typical of the 
strategy of latecomer firms leveraging their advantages. In in this case the knowledge of the 
regulatory process, established presence on the Chinese pharmaceutical market and low 
cost qualified scientific personnel, in exchange for the access to advanced knowledge, value 
and distribution chains of foreign partners or acquired foreign subsidiaries (Mathews, 
2002). It also illustrates the contribution of returnees to China’s nascent biotechnology.  
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Two cofounders, father and son, established the company in 1993, under the name 
Shenyang Sunshine. The father graduated from the Third Military Medical University, one 
of China’s leading medical research universities.  His son received the Ph.D. from Fordham 
University in the U.S. for work on interferon and completed his post-doctoral study at the 
U.S. National Institute of Health. Prior to joining Shenyang Sunshine Pharmaceutical 
Company Limited, the son founded Lifegen, Inc., a Maryland Corporation involved in 
optimizing the manufacturing processes for EPIAO and TPIAO. Lifegen is an investee 
company of Shenyang Sunshine. Two other two top executives of 3SBio also studied and 
practiced abroad, in the U.S. and Canada.  
3SBio Inc. received the New Drug Certificate for the bio-similar recombinant 
human Interferon INTEFEN and INLEUSIN in 1995 and started large scale production. In 
the same year, it initiated the R&D program that developed EPIAO (bio-similar to 
AMGEN’s EPO) and TPIAO (bio-similar to TPO) with support from the National 863 
project. EPIAO obtained New Drug Certificate in 1997, production license in 1998 and 
three years later it became the best-selling EPO in China. After longer development, 
TPIAO gained the New Drug Certificate and good manufacturing practices from the SFDA 
in 2005.   
The company incorporated in 2006 in Cayman Islands and had a very successful 
IPO on NASDAQ raising $135 million in 2007. In 2013, it delisted from Nasdaq and went 
private.  
The employment of the company increased from 320 persons in 2006 to 891 
persons in 2013. Its operations consist of bulk manufacturing and formulation of drugs used 
in cancer treatment and viral diseases. It distributes their products in 31 provinces, and its 
drugs are used in more than 3 500 hospitals (General Biologic, 2009)  
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To expand their market and competence in new fields, 3SBio partnered with and 
acquired from AMAG (U.S.) the exclusive license for obtaining SFDA’s approval for 
AMAG’s principal nephrology and oncology product Feraheme and its commercialization 
in China. Later 3SBio also partnered with and invested in a smaller cash-strapped Canadian 
company ISOTECHNICA, to develop and commercialize in China its ‘next generation’ 
drug complementary to FERAHEME, used in the prevention of rejection of transplanted 
organs and treatment of autoimmune diseases. Both partnerships provide complementary 
knowledge, and they were instrumental in establishing 3Sbio in the nephrology and 
oncology field.   
In addition to these first two North American partners, 3SBio has collaboration 
agreements with several Chinese companies, and one from Hong Kong. Lastly, 3SBio 
formed a joint venture with a leading U.S. dialysis services provider Da Vita, a Fortune 500 
company. The agreement will enable 3SBIO to enter the dialysis service market, starting in 
Jilin and Lianing provinces (Bioplan Associates, 2008 and Annual reports to the U.S. 
Securities and Exchange Commission). 
Manufacturers of Vaccines and Blood Products 
This branch is dominated by large firms established before the 2nd WW. The 
largest, the China National Biotech Group (CNBG) with eight regional subsidiaries 
controls 90% of China’s vaccines included in the National Immunization Program (NIP) 
and about 50% of type II vaccines.   More than half of enterprises in the second group are 
specialized producers of vaccines, 20% specialize in hematologic products, and the rest are 
combining vaccine manufacturing with recombinant products. The average size of the firm 
in this group is twice as large (472 employees) as the firms in the recombinant protein 
group.  (Bioplan Associates, Inc. 2008).The expanding state-subsidized NIP drives the 
development of vaccines and blood products. Domestic producers control completely the 
planned immunization market (Yezhou, L., 2010).  
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The CNBC became in November 2013 the first ever Chinese vaccine manufacturer 
to receive the WHO pre-qualification certification of approval for quality, safety and 
efficacy that allows CNBG to sell globally its vaccine against Japanese encephalitis,  a 
mosquito-borne disease, that kills 15 000 children each year. China now has the largest 
vaccine manufacturing capacity in the world, producing more than 1 billion vaccine doses 
annually. The WHO approval opens the door for China’s entry into the global vaccine 
market. 
The growing affluence of the urban population provides a market for vaccines of 
foreign origin, which are more trusted than the local products. Most novel vaccines are 
marketed by foreign MNC.  For example, Sanofi launched an influenza vaccine production 
in Shenzhen in 1996 and expanded the production in 2012. GSK also started production of 
influenza vaccine in Shanghai in 2004.  
Innovative biotechnology-based medicines  
The first Chinese successful modern biotechnological therapeutic product ‘Recombinant 
human interferon’ was developed by Shenzhen Kexing Biotech Co. and commercialized in 
the early 90s. By 2007, there were about 200 modern, innovative biotech firms that 
launched 35-biotech drugs in the domestic market. Among them the world’s first-gene 
therapy product “Gendicide” for treatment of solid tumors, developed and manufactured by 
Shenzhen Sibiono Gene Tech (Bioplan Associates, Inc., 2008).  
The Chinese State Drug and Food Administration (SFDA) approved between 225-chemical 
and biological drugs 2003 and 2010 (29 for marketing and 196 for clinical trials) developed 
by Chinese domestic companies. Both categories include only original chemical and 
biological drugs not yet approved anywhere in the world.  Out of the 187 investigational 
new drug applications 70 are protected by Chinese patents, 23 by U.S patents and 16 are 
patented in Europe. (Jingzong Qi et al. (2011).   
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4.2 The Size and Performance of Industries Manufacturing 
Biotechnology-based Medicaments and Medical Equipment & 
Appliances  
The rapid growth of the pharmaceutical sector is driven by the strong demand generated 
by the acceleration of the Chinese health- care. By 2013, medical insurance has covered 
95% of the population, and another 3% should be added by 2015.  
In 2010, China counted 862 enterprises manufacturing biopharmaceuticals, employing 
about 142 thousand persons and generating sales revenue of 152.5 billion Yuan (23 US$ 
billion).  They represent about 11% share of sales of the whole pharmaceutical sector, 
compared to 6.7% in 2000. In comparison, the share of sales of manufacturing of chemical 
medicines declined in the same period from 59.5% in 2000 to 49%.  
Medical equipment was manufactured in 1310 enterprises, employing 233 thousand 
employees, reporting 136 billion Yuan (US$20.6 billion) of annual sales in 2010, compared 
to US$11.5 billion in 2000.  
A comparison of the growth of the principal industries of the pharmaceutical sector is in 
Figure 5.  The two ‘new industries’ BBM and MEA are in the early phase of the life cycle 
of their technology systems. Their growth rate of output, sales and profits surpassed the two 
incumbent industries, manufacturing of chemical (CM) and traditional Chinese (TC) 
medicines.  
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Figure 5. Index of Gross Output of Chemical pharmaceuticals Chinese medicines, 
Biological products and Medical Equipment & Devices 
 
 
   (Enterprises with annual sales over 5 million Yuan, Const. prices 2000=100) 
 
0
200
400
600
800
1000
1200
1400
1600
2000 2005 2008 2009 2010 2011
    Man. of Chemical
Medicine
    Man. of Chinese
Medicine
    Man. of Biological
products
Man.of Medical Eqpt.&
appliances
Source: High Technology Yearbook, 2012, Table 1-1-3. 
Exports 
An increasing share of biological products and medical equipment & devices 
production was exported, respectively about 11% and 30% in 2010. However, relative to 
Chinese exports of electronic and computer products, the combined value of exports of 
biotechnology and medical equipment products is still minuscule, accounting for about 
1.5% of total exports by the high-technology sector in 2011, i.e. less than a half percent of 
China’s total exports.  
Performance of foreign-invested enterprises  
More than thirty years after China opened to foreign investment, two-thirds of 
China’s high-technology production is manufactured by foreign-invested firms. Big 
Pharma multinationals have been selling their brands in China since the early 90s, some 
even much earlier. Even though the top ten MNCs hold between 10% and 20% of Chinese 
Is China Catching up Human Health-related Applications of Biotechnology ? 
CIRST – Note de recherche | page 29 
drug market, the world’s top 15 pharmaceutical firms derived just 0.9% of their combined 
revenues from the Chinese market and 2.9% from the combined markets of Brazil, India 
and Russia (IMAP, 2011). By now, most Big Pharma have established in China joint 
ventures or whole-owned subsidiaries manufacturing mainly high quality, low cost active 
pharmaceutical ingredients (APIs), for their own use in China and their home countries. 
In comparison with other Chinese high-tech industries such as manufacturing of 
electronics or computer equipment where foreign-invested firms produce respectively 63% 
and 92% of industry’s output, their share of production of biopharmaceutical and medical 
equipment & devices industries is respectively 25% and 40%, well below the average of all 
high-tech industries (66%) in 2011. 
The rapidly growing personal income, the ongoing health reform and improving 
health services, improving protection of intellectual property, and regulatory system are 
making the Chinese pharmaceutical market increasingly attractive for Big Pharma 
multinational companies (Baeder and Ziegenziler, 2010). 
Foreign-invested enterprises (FIE) are the most productive segment of the 
biopharmaceutical and medical equipment industries. They export significantly more than 
their local counterparts.  Their average labor productivity of FIE is higher by a third than in 
the non-state owned firms and those invested from Hong Kong and Macao, and two and 
half times higher than productivity in the state-owned enterprises (SOE).  SOEs stand out 
as being the largest employers producing the smallest output per person.   
The source of higher productivity of FIE is not only their technological and 
administrative superiority. They are also significantly more capital intensive than their 
undercapitalized local competitors. 
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The more efficient FIEs accelerate the desirable consolidation of the pharmaceutical 
industry and enhance efficiency of local competitors. But in the process foreign firms may 
eliminate promising but undercapitalized small local competitors poorly served by the 
Chinese inefficient capital market. Multinationals also compete successfully for the scarce 
human resources. 
4.3 Enterprise Investment in R&D  
Enterprises manufacturing biotechnology-based drugs were from 2000 to 2010 on 
average more profitable by about 3 percentage points than other pharmaceutical firms and 
more than twice as profitable as all high-technology industries. 
Despite their profitability, still only about 40% of biopharmaceutical enterprises 
invested in R&D in 2010; i.e. more than firms manufacturing chemical medicines (35%) 
and medical equipment enterprises (28%), but insufficient to sustain an innovation-based 
growth.  The R&D expenditures of the Chinese pharmaceutical sector were less than 2% of 
the Gross industrial output value (GIOV), compared to 26.6% in the U.S., 25% in the UK, 
16.4% in Japan and 8.3% in Germany.   Chinese pharmaceutical companies’ R&D and 
innovation activity are still lagging far behind the leading industrial countries. Even most of 
those enterprises that conduct R&D are developing ‘me too’ imitations of foreign products 
and technologies rather than more original drugs. 
It can be argued, however that owing to the low cost of Chinese R&D personnel and the 
large percentage of firms that do not conduct R&D, the research intensity measured by the 
percentage of sales spent on R&D underestimates the actual R&D intensity of innovating 
firms.   Therefore, research intensity in this paper is measured by the R&D personnel’s 
share of total employment in large and medium size enterprises (Figure 6). 
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Figure 6. Evolution of the Share of R&D in Total Employment in Large and Medium Size 
Enterprises (% of Full-time equivalent person-year) 
 
 
Sources:China Statistical  Yearbook on High Technology, 2012, Tables        
1-1-4 and 2-1-3  
 
Structure and performance of R&D  
Exceptionally, for 2009 exist R&D data for all firms with annual sales over 5 
million Yuan, classified by size (Large, Medium and Small).   The data provide a more 
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larger incumbent manufacturing of chemical medicines. The four ratios in the right-hand 
part of the Table 4 illustrate the structures and compare the performance of the three 
industries, by small, medium, large size and ‘all’ enterprises in 2009. 
Ratio 1. The propensity to engage in R&D activities varies among the three 
industries and even more among firms of different size. Biological and chemical medicine 
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the smaller ones. Not so in the nascent biopharmaceutical industry, where only one of the 
two large enterprises was conducting R&D in 2009.   
Ratio 2. Small biopharmaceutical firms are more R&D intensive. The intensity of 
R&D in small firms manufacturing biological drugs was in 2009 almost twice as high 
(6.3%) as in small chemical firms (3.5%) and about as high as in large chemical firms. On 
the other extreme, the R&D intensity of the only two large biopharmaceutical 
manufacturers was only 1.3%.     
 Ratio 3. The lower the number of R&D person-years per patent, the higher the 
productivity of R&D. R&D productivity is higher in both new industries than in the 
incumbent manufacturing of chemical medicines. As predicted by the SSIP model, 
technological opportunities are more abundant at the early stage of the biotechnology 
system than in the mature stage of the chemical technology (Perez and Soete, 1988). It is 
yet another evidence of the declining productivity of the drug research in incumbent 
chemical technology-based innovation model.  
Ratio 4. Finally, the last column shows labor productivity, i.e. the value of output 
per unit of labor, in each industry by firm size category. On the one hand, it shows 
convincingly, that under the existing prices, irrespective of the firm size category, 
biotechnology-based drug manufacturing is more labor-productive than the incumbent 
manufacturing of chemical medicines. The low labor productivity in the medium and small 
size medical equipment firms may be due to a combination of low-technology products and 
high proportion of unqualified, low-cost labor employed mostly in assembly activities. A 
micro-econometric analysis of enterprise data could explain the sources of industry 
differences in innovation and productivity more completely.  Unfortunately, the enterprise 
data are not publically available and could not be used in this paper.  
Is China Catching up Human Health-related Applications of Biotechnology ? 
CIRST – Note de recherche | page 33 
The simple ratios analysis above suggests that biotechnology-based drug 
manufacturing is more R&D intensive, innovative and labor productive than the 
incumbentchemical drug manufacturing.  
 
Table 4. Number of Enterprises, Employment, Output, R&D Employment and Patenting 
R&D activities of the Big Pharma  
After setting up distribution channels and local manufacturing, often in joint 
ventures with local drug companies, ‘Big Pharma’ companies are increasingly off-shoring 
to China some of their R&D and clinical trials. According to a survey, pharmaceutical 
multinationals invested in their laboratories in China more than 8 Yuan billion /year (about 
1.25 US$ billion) in R&D, representing 57% of China’s pharmaceutical industry’s total 
R&D expenditure in 2012 (Christie, 2012). Their R&D expenditures are about 10% of 
revenues, compared to the China’s local industry’s average of 2%. Their firms created 210 
partnerships with universities, hospitals and academic institutions, including graduate 
degree programs. They were employing in 2012 about 3 000 R&D personnel of which 21% 
are returnees. 
 
Enterprise  Enterprises no. Employment Output Patents Ratio 1 Ratio 2 Ratio 3 Ratio 4 
Size Total with R&D Total R&D GVIO count Enterprise 
 with R&D/Total 
Employment 
(RD/Total) 
R&D productivity 
R&Demp /PAT 
Labor productivity 
GVIO/EMPyuan/emp 
             Column no.   (1)      (2)    (3)    (4)    (5)    (6)   (7)=(2)/(1)  (8)=(4)/(3)   (9)=(4)/(6)  (10)=(5)/(3)    
Chemical Medicines            %        %   
Large           2009                 50        41 207 826 13 781 1 341    795     82.0       6.6      17.3          64.5 
Medium      2009     507      335 334 458 17 676 2 119    967     66.0       5.3      18.3          63.4 
Small           2009  1 937      505 225 312   7 788 1 431    691     36.0       3.5      11.3          63.5 
All                2009  2 494      881 767 596 39 245 4 891 2 453     35.0       5.1      16.0          63.7 
Biological products           
Large           2009        2         1     6 265        80   63.4     10     50.0       1.3        8.0        101,2 
Medium      2009      89       61   54 507   5 106 391.1   284     68.0       9.4      18.0          71,8 
Small           2009    724     257   68 264   4 283 526.0   464     36.0       6.3        9.2          77,1 
All                2009    815     319 129 036   9 469 980.5   758     39.0       7.3      12.5          76,0 
Medical Equipment                   
&   appliances 
         
Large           2009        7         5   21 596   1 718 111.1   122     76.4        8.0      14.1          51,4 
Medium      2009    132       64   90 208   3 805 372.0   322     48.5        4.2      11.8          41,2 
Small           2009 1 123     283 121 218   3 669 490.4   922     25.2        3.0        4.0          40,5 
All                2009 1 262     352 233 022   5 523 973.5 1 366     27.9        2.4       6.7          41,8 
 
         Sources : China Statistical  Yearbook on High Technology 
(2008,2009; Tables 1-2-3; 2-5-3; 2-20).    
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The effects of spillovers from MNC’s production and R&D activities on the locally-
owned segment of the industry are expected to be very positive. However, the studies of the 
effect of foreign-invested firms on the performance of their locally-owned competitors in 
Chinese manufacturing industry do not support these expectations (Fu and Gong (2011). 
Foreign firms have few interactions with local firms that could promote technological 
learning, and they do not share the latest technologies (Wang, 2006). 
Contract research organizations  
As Big Pharma companies in developed countries are being challenged by the 
manufacturers of generic and bio-similar medicines, escalating R&D costs, patent 
expirations, increased scrutiny from regulatory agencies and institutional procurement of 
pharmaceuticals and medical devices, they seek to increase efficiency and reduce costs by 
outsourcing an increasing number of research activities to Contract Research and 
Manufacturing Organizations (CRO and CMO) abroad.  
The first few CROs established in China were foreign multinational companies 
(MDS, Quintiles, Covence, PPD and others) and joint ventures (Kendle Wits, Venture 
Pharm, Rundo, Pharmaron).  The domestic CROs entered the market after 2000, many of 
them providing contract services to generate revenues needed for their own R&D projects 
(Louet, 2004). In 2011, China’s total CRO market was approaching US$ one billion, 
growing more than 20% per year and ranking third in Asia, behind India and Singapore 
(Christie, 2012). 
Among the 22 major CROs, only six had biotechnology capabilities in 2004-2005 
(Zhou, 2007). Since then the share of CROs providing biotechnology services increased to 
40% in 2011. Foreign-invested CROs dominate all phases of clinical trials and share the 
market with the two largest domestic CROs, WuXi and Shang Pharma (Ma, 2012).  Their 
development has been based on expanding expertise by mergers and acquisitions abroad 
and in China.  
Is China Catching up Human Health-related Applications of Biotechnology ? 
CIRST – Note de recherche | page 35 
After a very successful IPO on NYSE in 2007 that raised $185 million, WuXi 
PharmaTech merged in 2008 with AppTec Laboratory Services Inc., a U.S. company with 
expertise in medical-devices, biologics testing and cell therapy. That opened WuXi the U.S. 
market and extended its capabilities from chemical to biological medicines and medical 
device expertise. It now provides the full range of R&D services in China and the U.S. 
Three-quarters of its revenue of $578 Million in 2013 originated in laboratory services 
(21% in the U.S.) and the rest in manufacturing services ($147 Million). It is one of rare 
Chinese U.S. listed health care companies with a growing stock price.  
The foreign and top Chinese CROs are the principal beneficiaries of the Big 
Pharma’s strategy of reducing the cost and sharing the risk by outsourcing to China, some 
of their R&D activities, including drug discovery.  
4.4 Catching up on the Global Scene?  – The Evidence from Patenting 
in China and the US. 
Like the rest of the high-tech industry, after introduction of TRIPs compliant patent 
regime, Chinese biotechnological and medical equipment companies started patenting 
aggressively.  
Patenting in China 
The average annual growth rate of the number of patents awarded by the Chinese 
State Intellectual Property Office (SIPO) from 2000 to 2011 to biopharmaceutical 
enterprises in China reached 33% (Figure 7).  
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Figure 7. Number of patents granted by the Chinese Patent Office to Bio-
pharmaceutical, Chemical, Chinese and Medical equipment industries 
Source: China Statistical Yearbooks on High Technology, 2008 (Table 2-20) and 2010, 2012  
(Tables 2-5-1).  
Note: Includes enterprises over designated size, i.e. Large, Medium and Small size with annual 
sales over 5 million Yuan 1995-2010 and over 20 million Yuan 2011. 
 
Patent statistics shows that small firms play an essential role in the development of 
an innovative Chinese biopharmaceutical industry. The share of biotechnology patents 
owned by small firms is larger (54%) than their share of industry’s output (46%) and 
employment (42%). Obviously, biotechnology provides abundantly technological 
opportunities that attract new firms.  
The contrast with small firms manufacturing chemical medicines is telling. Their 
share of patents for chemical pharmaceuticals is only 25%, compared to employment and 
output share (both about 29%). Patenting by small firms in medical equipment and 
appliances industry is slightly lower than their share of output and employment.  
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The foreign-invested biopharmaceutical firms are the most innovative. Their share 
of the total number of patents awarded to China’s bio-pharmaceutical industry is 36%, 
more than their share of output (31%) and employment (27%) and also more than the patent 
share of foreign-invested producers of chemical drugs (31%).  
The surge of patenting in China in the last decade is an evidence of the growing 
awareness of the importance of intellectual property and increasing innovation in 
manufacturing of biopharmaceuticals. It is, however, not a good benchmark of China’s 
biotechnology catching up with the world biotechnology leaders. This purpose is better 
served by the share of biotechnology patents obtained by Chinese patentees in the U.S., the 
first, most advanced country in biotechnological research and its industrial applications. 
Patenting in the US  
The cumulative number of U.S. patents for biotechnological inventions listing a 
Chinese inventor or co-inventor increased notably after 2000, reaching 740 patents in 2013. 
Patentees from the U.S., Eu, Japan and few other countries own almost half (354) of 
thethem. The inventors were presumably Chinese nationals studying and working in U.S, 
EU or Japanese organizations in the given period.
4
 
Since the purpose of the analysis is to assess whether Chinese biotechnology is 
catching up with the biotechnology frontier, Table 5 includes only 386 USPTO patents 
assigned to organizations and individuals with an address in P.R of China. Their number 
has been growing exponentialy.  
The composition of patentees has dramatically changed. Before 2004, the majority 
of US biotechnology patents were awarded to Chinese universities, public research 
institutes and individuals; only very few to enterprises. Considering 2005 as the first year of 
full Chinese compliance with TRIPS, the share of US patents awarded to Chinese 
                                                 
4
 It is recognized that after their return to China, some of them may have contributed with their subsequent 
inventions there to USPTO patents assigned in later periods to Chinese entities or individuals.  
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enterprises has significantly increased from 17% in 1989-2004 to 38% in 2005-2013. This 
suggests that TRIPs have provided powerful incentives for local innovation and patenting 
to which Chinese universities, research institutes and especially enterprises responded 
vigorously (see Table 5 for details). More recent data on Chinese international patenting of 
biotechnology inventions under the Patent Cooperation Treaty confirm the increasing trend. 
The upward trend supports the hypothesis of a catch up, but the gap separating China’s 
biotechnology industry from the leaders in the field is still very large.  
Table 5.   US patents to Chinese inventors assigned to Chinese entities and individuals 
(Patents to Chinese assignees only ) 
 
Year Enterprises 
Universities &  
Research Institutes Individuals 
 
Co-ownership 
within China Total 
 1989-1994 1 2 1 
 
0 4 
 1995-2000 
 
7 4 
 
5 16 
 2001-2004 9 13 5 
 
11 38 
 2005-2009 41 33 8 
 
18 100 
 
2010-2013 85 79 35  29 229  
Total 136 133 53 
 
63 386 
  
Source: Author’s tabulation of patents from the U.S.PTO.  
Methodology. The selection criteria: (1) Patents in international patent classes listed as 
biotechnology by the OECD (2003), awarded to inventors and co-inventors with address in the 
P.R. of China. Patents to inventors from Hong Kong, Macau or Taiwan are not included. Each 
patent is counted only once.  
(2) Slightly more than one half (386) of the total of 740 patents with Chinese inventors or co-
inventors assigned to Chinese organizations and individuals are classified manually by the type 
of assignee in one of the five categories above.  
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5. Discussion and conclusions  
The paper examines how far China has advanced in its goal of catching up with leading 
industrialized countries in modern biotechnology. The Sectoral System of Innovation and 
Production (SSIP) complemented by strategic considerations of latecomer firms appeared 
to be the best suited approach. The first views the catch up as a learning process; the second 
considers the strategies by which the latecomer firms are overcoming competitive 
disadvantages through linkages, resource leverage and learning; learning being the common 
denominator of both perspectives.  
5.1 Recapitulation of the main findings 
Scientific capabilities  
The first empirical part of the paper examines (1) the effects of reforms on building 
a sustainable knowledge base for the development of the biotechnology regime and (2) 
whether the radical restructuring of the Chinese scientific infrastructure is reducing the gap 
separating China’s scientific research from biotechnology forerunners.  
China’s higher education system is already training more scientists and engineers at 
the doctorate level than any other country in the world as befits her scientific ambitions. 
The education is, however, reflecting the top-down thinking proper to China’s political 
system. It praises memorizing more than free individual initiative, and it does not tolerate 
failure, a quality indispensable for bold innovation. The government has been 
underinvesting in basic research and to make things worse, PROs do more development 
than scientific discovery-oriented research. The statistical system pays insufficient attention 
to small firms, the most likely and dynamic source of radical innovations. Small firms are 
also treated less generously by R&D incentives than the large ones. 
The growing numbers of highly qualified personnel returning from the U.S. and 
Europe to China help to improve and accelerate the development of Chinese biotechnology 
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research base and encourage R&D and innovation. Their continuing active links and 
collaboration with their former foreign professional networks is the best channel for 
learning and diffusion of new ideas, technologies and market opportunities. It certainly 
helps to reduce the gap between Chinese and Western biotechnology research and 
applications.  
The reorganization of the scientific infrastructure improved its quality and 
productivity. Despite the low level of basic research, the number and quality of Chinese 
scientific publications in biotechnology have been increasing much faster than the scientific 
personnel employed in biotechnology research. The knowledge base of the SSIP of human 
health-related applications of biotechnology in China is well advanced in the catch up 
process. The rapidly growing world’s largest ‘genomic research factory’ BGI-Shenzhen 
exemplifies the Chinese strategy of creating a competitive advantage through linkages, 
resource leverage and learning from incumbents. 
Industrial applications of biotechnology 
The majority of enterprises in the biotechnology-based component of the 
pharmaceutical sector are manufacturing APIs and biosimilar drugs often under the license 
or contract from foreign firms in China and abroad. An increasing number of Chinese 
biotechnology firms are engaging in discovery and development of innovative APIs, 
incremental innovation and some world-first ones. Most of these innovative products are 
still in the approval process of the SFDA and not yet on the market.  The other, even faster 
growing ‘new industry,' Manufacturing of medical equipment and devices’ has been 
benefiting from the symbiotic relationship with the ITC and electronic enterprises and 
research laboratories co-located in the same clusters.  
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 Foreign invested firms are more export as well as research-intensive and more 
labor-productive than their local competitors. Even though most Big Pharma companies are 
present, their sales in China still account for less than 1% of their global sales, a suboptimal 
situation which their strategy of outsourcing to emergent markets is trying to correct. The 
rapid introduction of universal health insurance, ambitious plans for the development of 
biotechnology and pharmacology, as well as improvement of intellectual property 
protection and regulatory process, explain why most of the Big Pharma companies continue 
establishing or expanding R&D centers and CMOs in China as part of their global value 
chain. 
5.2 New niches and strategies  
New niches  
While most Chinese biotechnological companies pursue either the bio-similar or 
innovative strategy described above, some organizations are aggressively developing more 
specialized niches in biotechnology and related scientific disciplines. One outstanding 
example is GBI-Shenzhen’s drive to transform gene sequencing from a piece-meal 
expensive laboratory research procedure into a factory-like large-scale low-cost operation 
and open the way to personalized medicine (Spencer, 2014).  
Another is the active embryonic stem cell research which has been severely 
constrained or banned in many Western countries, including the U.S.  More relaxed 
regulations have opened a window of opportunity for Chinese researchers who are now 
recognized leaders in the field that may revolutionize the regenerative medicine (Murray 
and Spar, 2006). 
Biotechnology’s share of the pharmaceutical sector’s sales, investment and R&D 
has significantly increased; an evidence of a shift from chemical to biotechnology-based 
drug manufacturing. Their patenting, not only in China but also in the US and elsewhere 
abroad, has significantly increased. In contrast to very little patenting by the large, 
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incumbent manufacturers of chemical medicines (Niosi J., S. Reid and J. Zhao, 2013), new, 
mostly small biotechnology companies, responded to TRIPs-imposed international 
standards of protection of intellectual property by patenting aggressively in China and 
abroad. Even though the cumulative number of patents owned by Chinese entities pales in 
comparison with the patent chest of the U.S. biotechnology giants, their ascending trend 
may be interpreted as an early sign of catching up with the leaders in the field.   
Strategies   
The strong drive of MNCs establishing proprietary R&D centers and partnerships 
with Chinese universities, PROs and enterprises, is not only part of the Big Pharma’s new 
global cost cutting and risk sharing strategy. It is also a means to expand their share of the 
large and growing Chinese drug market.  The close cooperation between the U.S. FDA and 
their Chinese counterpart aimed at improving the safety and quality of the ‘Made in China’ 
APIs, generics and biosimilars are part of this globalizing strategy. 
Whether the short benefits exceed the future costs for the society in terms of 
increasing Big Pharma’s penetration of the Chinese drug market is less clear. It is obvious 
that it is not a zero-sum game. A comprehensive study of the long run effect of foreign-
invested firms on their local competitors, the development of pharmaceutical industry, life 
sciences and the welfare of the Chinese population does not yet exist. 
Several recent international deals described in the text show a new strategy of 
China’s foreign direct investment abroad. Chinese enterprises invest increasingly in High-
Tech sectors like pharmaceuticals (Niosi J., S. Reid and J. Zhao, 2013). Financially strong 
Chinese companies  are ‘buying-in’ the new knowledge, technological capabilities and 
access to foreign distribution channels in exchange for facilitating their partner’s products 
or services  entry on the Chinese market, or licensing it and distributing it on their own 
distribution networks. 
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Further development of the Chinese biopharmaceutical sector is likely to proceed by 
a combination of three strategies “borrowed” from the world of music:  
1.    Becoming a part of a global music scene by playing in a cosmopolitan orchestra 
directed by a foreign director (a Big Pharma company) and striving to increase the number 
of concerts given in China by adjusting its repertoire to Chinese needs and taste. 
2.   Pursuing the goal of becoming a well-known chef of one of China’s excellent 
orchestras by hiring impoverished foreign musicians when the local talent is not good 
enough or not available. Play Chinese and foreign music, especially the compositions or 
arrangements of its foreign members. 
3.     Becoming a world-renown virtuoso and composer for its own instrument and give 
concerts on the domestic and international music scene. 
5.3 Challenges ahead 
Like in Western countries, further development of Chinese life sciences-related 
biotechnology will be increasingly integrated in the pharmaceutical sector rather than 
developing more independently.  To become more innovative and bring own original drugs 
on the market, Chinese research in biotechnology will have to focus more on basic 
research. It has to aim at discovering original, ‘me first’ medicines, devices, services and 
procedures rather than continue to rely on ‘me too’ imitation and incremental innovation of 
foreign discoveries.  
The R&D support policies will have to concentrate on supporting rather than 
discriminating against small companies, the most likely fertile source of radical 
innovations. To properly manage the public support of small firms, better statistical 
coverage of these enterprises is necessary. Despite a concerted effort to improve the quality 
of regulatory procedures, the approval procedures are still too slow and their quality not 
always to international standards. Without an improvement of SFDA services quality and 
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timeliness, China’s attraction as a partner integrated with the global value chain of foreign 
multinational pharmaceutical companies will not fulfill its potential. Given the importance 
of the pharmaceutical sector for China’s huge drug market, the stakes of closer integration 
with Big Pharma are high and merit an in-depth study.   
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